C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.46M | 7.24M | 5.18M | 15.36M | 12.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.46M | 7.24M | 5.18M | 15.36M | 12.01M |
| Cost of Revenue | 26.20M | 27.07M | 32.51M | 31.84M | 23.75M |
| Gross Profit | -19.73M | -19.83M | -27.34M | -16.48M | -11.75M |
| SG&A Expenses | 8.77M | 9.33M | 10.37M | 11.77M | 9.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.96M | 36.40M | 42.89M | 43.61M | 33.45M |
| Operating Income | -28.50M | -29.16M | -37.71M | -28.24M | -21.44M |
| Income Before Tax | -26.02M | -26.32M | -34.44M | -24.67M | -17.72M |
| Income Tax Expenses | -- | -- | 131.00K | -- | -- |
| Earnings from Continuing Operations | -26.02M | -26.32M | -34.57M | -24.67M | -17.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.02M | -26.32M | -34.57M | -24.67M | -17.72M |
| EBIT | -28.50M | -29.16M | -37.71M | -28.24M | -21.44M |
| EBITDA | -27.89M | -28.71M | -37.23M | -27.80M | -20.99M |
| EPS Basic | -0.37 | -0.37 | -0.49 | -0.35 | -0.26 |
| Normalized Basic EPS | -0.24 | -0.23 | -0.31 | -0.22 | -0.19 |
| EPS Diluted | -0.37 | -0.37 | -0.49 | -0.35 | -0.26 |
| Normalized Diluted EPS | -0.24 | -0.23 | -0.31 | -0.22 | -0.19 |
| Average Basic Shares Outstanding | 71.01M | 70.83M | 70.61M | 69.63M | 68.81M |
| Average Diluted Shares Outstanding | 71.01M | 70.83M | 70.61M | 69.63M | 68.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |